Research & Reconstitution Library

AOD-9604 BAC Water & Reconstitution Guide

Q: How much BAC water for 10 mg of AOD-9604?

For mathematical concentration purposes, 10 mg divided by 1 mL equals 10 mg/mL, 2 mL equals 5 mg/mL, 2.5 mL equals 4 mg/mL, 3 mL equals approximately 3.33 mg/mL, and 5 mL equals 2 mg/mL.

Q: What is the AOD-9604 reconstitution formula?

For mathematical concentration calculations, concentration in mg/mL equals total compound quantity in mg divided by liquid volume in mL.

Q: Does adding more BAC water change the total amount of AOD-9604?

No. In a basic concentration calculation, changing liquid volume changes concentration but does not change the total quantity represented by the vial.

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone and has been investigated primarily in metabolic and lipid-research contexts. Human clinical development included intravenous and oral studies, but AOD-9604 does not have an established FDA-approved therapeutic use for obesity.

Quick research answer: There is no scientifically established universal amount of bacteriostatic water that applies to every AOD-9604 vial. The amount of liquid determines the resulting concentration. For example, a mathematical 5 mg vial would correspond to 5 mg/mL with 1 mL of liquid, 2.5 mg/mL with 2 mL, and 1 mg/mL with 5 mL. These are concentration calculations, not human dosing or administration instructions.

Compound AOD-9604

Compound Class Growth-hormone C-terminal fragment analogue

Research Category Metabolic / Lipid Research

Regulatory Status Not FDA-approved for obesity

Human Evidence Clinical studies conducted; efficacy not established

Research Form Commonly encountered as lyophilized research material

Concentration Unit mg/mL

Last Reviewed September 10, 2026

Concentration Calculator Reference

How Much BAC Water for AOD-9604?

The correct mathematical relationship is simple: concentration equals the total compound quantity divided by the liquid volume.

Total vial quantity ÷ Liquid volume = Concentration

Consequently, adding more liquid produces a lower concentration, while adding less liquid produces a higher concentration. The total amount of AOD-9604 represented by the vial does not change simply because the liquid volume changes.

Important: BacScience does not establish a universal AOD-9604 reconstitution volume, clinical dose, injection volume, frequency, or treatment protocol on the basis of these calculations.

Figure 1. Conceptual illustration of AOD-9604 and its historical research focus on metabolic and lipid biology. This is an educational schematic, not a molecular structure model.

Mathematical concentration examples

AOD-9604 BAC Water Concentration Chart

The table below demonstrates how different liquid volumes mathematically change the concentration of a 5 mg or 10 mg quantity. These figures are provided for concentration calculation and research planning only.

Vial Quantity	1 mL	2 mL	2.5 mL	3 mL	5 mL
5 mg AOD-9604	5 mg/mL	2.5 mg/mL	2 mg/mL	1.67 mg/mL	1 mg/mL
10 mg AOD-9604	10 mg/mL	5 mg/mL	4 mg/mL	3.33 mg/mL	2 mg/mL

Need a different vial quantity or BAC-water volume?

Use the BacScience Universal BAC Water Calculator to calculate concentration from custom quantities.

Open BAC Water Calculator

Calculation note: Concentration = total compound quantity ÷ liquid volume. For example, 5 mg ÷ 2 mL = 2.5 mg/mL. Actual product composition, salt form, purity, residual moisture, and manufacturer documentation can affect laboratory interpretation.

How Much BAC Water Should Be Added to 5 mg of AOD-9604?

There is no single scientifically established BAC-water volume that should be treated as the universal answer for a 5 mg AOD-9604 vial. Instead, the desired concentration determines the mathematical liquid-volume relationship.

Example A

5 mg ÷ 1 mL

Mathematical concentration: 5 mg/mL.

Example B

5 mg ÷ 2.5 mL

Mathematical concentration: 2 mg/mL.

Example C

5 mg ÷ 5 mL

Mathematical concentration: 1 mg/mL.

How does BAC-water volume change AOD-9604 concentration?

Increasing the liquid volume decreases concentration because the same total quantity of AOD-9604 is distributed through a larger volume. Decreasing the liquid volume produces a more concentrated mathematical solution.

How do you calculate AOD-9604 concentration?

AOD-9604 quantity ÷ liquid volume = concentration in mg/mL

Example: if the mathematical input is 10 mg and the liquid volume is 2 mL, then:

10 mg ÷ 2 mL = 5 mg/mL

The calculation does not establish a therapeutic dose, administration volume, injection schedule, or clinical protocol.

Figure 2. Mathematical concentration visualization. Increasing liquid volume lowers concentration while the total compound quantity remains constant.

Research calculation

Concentration Is Not the Same as Dose

One of the most important distinctions in peptide research is the difference between concentration and dose.

Quantity

The amount of compound represented by the vial, such as 5 mg.

Concentration

The amount of compound represented per unit of liquid, such as mg/mL.

Dose

An amount administered to a subject in a particular research or clinical protocol.

Do not interchange these concepts. A concentration calculation does not establish a human dose or determine whether a compound should be administered by any particular route.

What Is AOD-9604?

AOD-9604 is a synthetic peptide fragment associated with the C-terminal portion of human growth hormone. The published scientific literature describes AOD-9604 as Tyr-hGH_177–191, with research focused on the metabolic and lipolytic properties associated with this region of the parent hormone.

Unlike full-length human growth hormone, AOD-9604 was developed as a fragment intended to investigate lipid-metabolism effects without reproducing the complete growth-hormone molecule. Published human research specifically evaluated whether the peptide altered IGF-1 and glucose metabolism.

AOD-9604 Tyr-hGH 177–191 Hexadecapeptide Metabolic research Lipolysis research

How AOD-9604 Works

Mechanistic research

Lipid metabolism

Preclinical research investigated AOD-9604 for effects associated with lipolysis and lipid metabolism. Early laboratory and animal work provided the rationale for investigating whether the peptide could reproduce selected metabolic properties of the growth-hormone molecule.

Human evidence

Growth-hormone-axis markers

In published safety research, human studies measured IGF-1, glucose-related parameters and anti-AOD-9604 antibodies. The reported clinical studies did not show significant IGF-1 elevation attributable to AOD-9604.

Evidence distinction: Mechanistic observations, animal findings, safety observations and evidence of clinical efficacy are separate categories. A biological mechanism does not by itself establish that a compound produces a clinically meaningful outcome in humans.

What Is AOD-9604 Being Studied For?

Human clinical research

Obesity & body weight

AOD-9604 underwent human clinical development for obesity. The available regulatory assessment concluded that the evidence did not establish effectiveness for obesity.

Human studies

Preclinical research

Lipid metabolism

Animal studies investigated changes in adipose metabolism, lipolytic activity and body-weight-related outcomes.

Animal / laboratory

Anecdotal claims

Community protocols

Online communities may discuss injectable AOD-9604 protocols. Such community practices are not equivalent to controlled clinical evidence and are not used here to establish dosing recommendations.

Not clinical evidence

Human Clinical Research

AOD-9604 was evaluated in several randomized, double-blind, placebo-controlled human studies. A 2013 publication summarized six clinical trials conducted between 2001 and 2006, involving approximately 893 participants across the clinical program.

Importantly, the clinical program included intravenous and oral administration. This matters because the existence of human research does not mean that results from one route can be transferred to another route.

Study	Population	Research Dose	Route	Duration	Research Focus
METAOD001	15 healthy adult males	25–400 µg/kg	IV	Single-dose	Safety / dose escalation
METAOD002	23 clinically obese males	25, 50, 100 µg/kg	IV	Single-dose	Safety / tolerability
METAOD003	17 clinically obese males	9, 27, 54 mg	Oral	Single-dose	Safety / pharmacodynamic research
METAOD004	36 clinically obese males	9, 27, 54 mg/day	Oral	7 days	Safety / tolerability
METAOD005	300 obese adults	1, 5, 10, 20, 30 mg/day	Oral	12 weeks	Weight / safety research
METAOD006	502 obese adults	0.25, 0.5, 1 mg/day	Oral	24 weeks	Weight / safety research

Research-dose disclaimer: The doses in this table are historical doses reported in clinical research. They are not BacScience recommendations, treatment doses, or instructions for use.

Doses Studied in Published Research

Human studies examined multiple AOD-9604 exposure levels. The route, study design, population and purpose varied substantially between trials.

Intravenous research

The early human safety studies evaluated single intravenous doses ranging from 25 to 400 µg/kg in healthy or clinically obese adult males.

Historical clinical research

Oral research

Later studies evaluated oral AOD-9604, including single doses of 9, 27 and 54 mg, a seven-day study using 9, 27 and 54 mg/day, and longer obesity studies using lower daily doses.

Historical clinical research

Route matters: Published clinical research involving oral or intravenous AOD-9604 should not be interpreted as establishing a subcutaneous administration protocol. FDA's review specifically noted that it did not identify information on AOD-9604 products administered by subcutaneous or transdermal routes in humans.

Preclinical Research

Before and alongside human development, AOD-9604 was studied in animal models of obesity and metabolic dysfunction. These experiments explored effects such as lipolysis and changes in adipose tissue metabolism.

Animal evidence

Obese rodent models

Research in obese Zucker rats reported increased lipolytic activity and reduced body-weight gain under the conditions of the experiment.

Mechanistic evidence

Lipid metabolism

Experimental studies investigated how the peptide could influence lipid metabolism independently of some of the broader biological effects associated with intact growth hormone.

Translation limitation: Animal doses, routes and metabolic responses cannot be directly converted into human dosing recommendations.

Research Reconstitution & Concentration

For laboratory concentration calculations, the fundamental relationship is:

Concentration (mg/mL) = Total AOD-9604 (mg) ÷ Liquid Volume (mL)

Worked mathematical examples

Example 1

5 mg ÷ 1 mL

5 mg/mL

Example 2

10 mg ÷ 2.5 mL

4 mg/mL

Example 3

5 mg ÷ 5 mL

1 mg/mL

Important laboratory distinction: A calculated concentration is a mathematical property of the quantity and liquid volume. It does not establish sterility, stability, biological activity, compatibility, clinical suitability, or a human administration dose.

BAC Water vs. AOD-9604 Concentration

More liquid

Lower concentration

Keeping the compound quantity constant while increasing liquid volume reduces the mathematical mg/mL concentration.

Less liquid

Higher concentration

Keeping the compound quantity constant while decreasing liquid volume increases the mathematical mg/mL concentration.

Total quantity

Remains constant

Changing liquid volume does not magically create or remove the total quantity represented by the vial.

Calculate your own concentration

Enter a custom vial quantity and liquid volume.

Use BAC Water Calculator

Research Limitations & Safety

AOD-9604 should be interpreted within the limits of the available scientific and regulatory record. The compound underwent clinical development, but development for obesity did not establish a clinically meaningful therapeutic benefit.

FDA regulatory context

In its December 2024 Pharmacy Compounding Advisory Committee materials, FDA evaluated AOD-9604-related substances for obesity and concluded that available evidence did not support effectiveness for treatment of obesity. FDA also identified limited safety information and concerns related to physicochemical characterization and potential immunogenicity.

Human evidence limitations

AOD-9604 has not established an FDA-approved therapeutic indication for obesity.
Historical human studies used different routes and experimental designs.
Human clinical research cannot automatically be translated to modern research-vial formulations.
Published clinical exposure levels are not recommendations for self-administration.
No clinically established human dose should be inferred from the concentration calculations on this page.

Research-use warning: This page is educational scientific content. It does not prescribe, recommend, or establish human treatment with AOD-9604. Do not interpret the BAC-water examples as instructions for injection or clinical administration.

Frequently Asked Questions

AOD-9604 BAC Water & Reconstitution FAQ

How much BAC water should be used for AOD-9604?

There is no universal scientifically established BAC-water volume for AOD-9604. The liquid volume determines the resulting concentration. For example, 5 mg divided by 2 mL produces a mathematical concentration of 2.5 mg/mL. This calculation is not a clinical dosing recommendation.

How much BAC water for 5 mg of AOD-9604?

No single volume applies universally. Mathematical examples include 1 mL = 5 mg/mL, 2 mL = 2.5 mg/mL, 2.5 mL = 2 mg/mL, 3 mL = approximately 1.67 mg/mL, and 5 mL = 1 mg/mL.

How much BAC water for 10 mg of AOD-9604?

For mathematical concentration purposes, 10 mg ÷ 1 mL = 10 mg/mL, 10 mg ÷ 2 mL = 5 mg/mL, 10 mg ÷ 2.5 mL = 4 mg/mL, 10 mg ÷ 3 mL = approximately 3.33 mg/mL, and 10 mg ÷ 5 mL = 2 mg/mL.

What is the AOD-9604 reconstitution formula?

For mathematical concentration calculations: concentration in mg/mL = total compound quantity in mg divided by liquid volume in mL.

Is AOD-9604 FDA approved for weight loss?

No FDA-approved therapeutic indication for AOD-9604 for obesity is established by the regulatory record discussed on this page. FDA's 2024 review concluded that available evidence did not support effectiveness for obesity.

Has AOD-9604 been studied in humans?

Yes. Human clinical studies investigated AOD-9604 using intravenous and oral administration. A published safety summary describes six randomized, double-blind, placebo-controlled studies involving approximately 893 participants across the program.

What doses of AOD-9604 were studied in humans?

Historical clinical studies investigated different experimental exposure levels, including intravenous doses of 25–400 µg/kg and oral studies ranging from 0.25 mg/day to 54 mg/day depending on the study. These are historical research exposures and are not recommendations for treatment or self-administration.

Does adding more BAC water change the total amount of AOD-9604?

No. In a simple concentration calculation, changing the liquid volume changes concentration but not the total quantity of compound represented by the vial.

Does concentration equal dose?

No. Concentration is an amount per unit volume, such as mg/mL. Dose refers to an amount administered to a subject within a particular research or clinical protocol.

Can animal AOD-9604 doses be converted to human doses?

No simple conversion should be used. Animal studies and human studies can differ in species, pharmacokinetics, route, exposure and biological response. Animal findings should remain clearly separated from human clinical evidence.

Is AOD-9604 the same as human growth hormone?

No. AOD-9604 is a synthetic peptide fragment associated with the C-terminal region of human growth hormone. It is not full-length recombinant human growth hormone.

Where can I calculate a custom AOD-9604 concentration?

The BacScience Universal BAC Water Calculator can calculate concentration using a custom compound quantity and liquid volume. Open the BAC Water Calculator .

Related BacScience Research Resources

Calculator

BAC Water Calculator

Calculate concentration using custom vial quantities and liquid volumes.

Open BAC Water Calculator →

Research Library

Research Compound Library

Explore additional compound research and concentration resources.

Research Compound Library →

Testing

Testing & Transparency

Learn about laboratory testing, certificates of analysis, identity verification and batch documentation.

Testing & Transparency →

Developer note: The links marked with # intentionally require URL insertion after the final BacScience Research Library architecture is confirmed. No unverified internal URLs have been fabricated.

Scientific References

U.S. Food & Drug Administration — AOD-9604 Related Bulk Drug Substances Evaluation
FDA Pharmacy Compounding Advisory Committee materials, December 2024.
View FDA briefing document

Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans.
Journal of Endocrinology and Metabolism. 2013;3(1-2):7–15.
Read the publication

Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.
Hormone Research. 2000;53(6):274–278. PMID: 11146367.
View PubMed record

Wilding JP. AOD-9604 Metabolic.
Current Opinion in Investigational Drugs. 2004;5(4):436–440. PMID: 15134286.
View PubMed record

Detection and in vitro metabolism of AOD9604.
Drug Testing and Analysis. PMID: 25208511.
View PubMed record

FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.
FDA regulatory information concerning AOD-9604 and limitations in available safety information.
View FDA resource

Last Scientifically Reviewed

September 10, 2026

This page was reviewed against available FDA regulatory materials and published scientific literature concerning AOD-9604, including human clinical research and preclinical metabolic research.

Scientific reviewer: BacScience Scientific Content Team
Content scope: Research education, concentration mathematics and scientific literature interpretation.